So, what happens when the US decides it no longer wishes to subsidise the world?
The importance of the US market to proprietary pharmaceutial companies was emphasised this week by the news that GlaxoSmithKline has announced a dive in profits. Despite strong sales growth in both Europe and Asia, GSK saw a 13% decline fall in its…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.